Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Background: The everolimus–exemestane pair was approved by the US Food and Drug Administration (FDA) in 2012 to treat women with hormone receptor-positive (ER+), HER2-negative metastatic breast cancer (MBC) that got worse after treatment with aromatase inhibitor alone. The main benefit of this...
See discussions, stats, and author profiles for this publication at: https://.researchgate.net/publication/15093941 Her-2/neu Expression in Node-negative Breast Cancer: Direct Tissue Quantitation by Computerized Image Analysis and Association of Overexpression with Increased Risk of Recurrent Di... ...
[5] Finn, R. S. et al. Overall Survival (OS) With First-Line Palbociclib Plus Letrozole (PAL+LET) Versus Placebo Plus Letrozole (PBO+LET) in Women With Estrogen Receptor-Positive/Human Epidermal Growth Factor Recept...
The triple-negative breast cancer (TNBC) is a deadliest type of breast cancer, comprising 20 percent of breast cancer cases. It is estrogen receptor-negative, progesterone receptor-negative and HER2-negative, meaning it is resistant to all the three effective breast cancer targets. ...
Change in HER-2/neu status from negative to positive following treatment has not been well studied. We describe a patient with inflammatory breast cancer who was initially HER-2/neu negative but became positive after treatment. A 59-year-old postmenopausal white female saw her surgeon for viola...
[4] Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020;38(5):444-453. ...
(HER-2/neu) and which represents a subset of breast cancer with different biologic behavior. We investigated the clinicopathological characteristics and prognostic indicators of lymph node-negative TN breast cancer. Medical records were reviewed from patients with node-negative breast cancer who underwent...
The triple negative breast cancer is a unique entity that has been shown to be basal.1,2 This is definitely not one disease; genomic and microarray assays have shown this to be inhomogeneous cancer. Though we could not perform the genomic assay, had it been done we believe we could have ...
The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancerYu, K.-D.; Shen, Z.-Z.; Shao, Z.-M.Breast Cancer Research and Treatment 118(3): 661-663...